Teva gets tentative FDA OK for generic Norvasc

03/28/2005 | NYTimes.com

Teva Pharmaceutical received tentative FDA approval for marketing its generic version of Pfizer's Norvasc for treating hypertension and angina, worth $2.4 billion in annual sales for Pfizer. Teva said it expects final agency approval once Pfizer's patent on the drug expires in September 2007.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA